No, and if the trial continues after the 75% interim look, we might not see that PRed either...
Amarin has one drug under development right now. Everything is material for that to the company. AZN is huge and has a zillion drugs under development -- an interim look for one trial isn't material, and so they have no requirement to PR that.
The end of the trial would be material -- that they would have to disclose. Good end or bad end.
News 
Market Data 
Discover 
